Onglyza Lawsuit

Whether you're a patient or a doctor who's treating patients, you should be aware of the Onglyza lawsuit. It's been reported that patients taking this drug have developed serious side effects, including heart failure. As a result, it may be possible to file a lawsuit against the drug manufacturer, AstraZeneca, and Bristol-Myers Squibb.

Heart failure side effects

Despite being considered a promising new treatment option, Onglyza (a drug used to treat diabetes) has been linked to a higher risk of heart failure. According to a study published in the New England Journal of Medicine, 3.5 percent of patients who took the drug suffered from heart failure. Onglyza is a member of a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by reducing blood glucose.

The FDA issued a safety warning in 2014, warning that the risk of heart failure associated with saxagliptin-based type-2 diabetes drugs is higher than previously known. The warning was based on results of randomized clinical trials. The study showed that saxagliptin increased the risk of heart failure hospitalization by 27 percent, compared to 2.8 percent among patients who were given a placebo.

The FDA's findings were based on a study of over 16,000 patients who participated in the EXAMINE trial. The study observed these patients for 18 months.

AstraZeneca and Bristol-Myers Squibb's response to the lawsuits

During the last year, the pharmaceutical company Bristol Myers Squibb has launched lawsuits against AstraZeneca and Merck. The lawsuits cite eight counts of patent infringement. They seek an injunction against further infringement and compensation for damages.

The lawsuits seek to halt the use of AstraZeneca's drug, Imfinzi, which is approved to treat lung and bladder cancer. The drug works in a similar way to Opdivo, which is sold by Bristol Myers. It binds to programmed death-1 receptors on immune cells, enabling the immune system to attack cancer cells.

Imfinzi has brought in over $2.45 billion in sales since its launch in 2014, despite having a number of serious side effects. The company has also filed patent infringement lawsuits against Roche and Merck.

According to the lawsuit, AstraZeneca violated the patents of Opdivo by marketing Imfinzi. Bristol Myers Squibb claims that Imfinzi infringes on eight of its patents. It earned $7.5 billion in sales for Opdivo last year.

Whether a class action lawsuit will be filed

Whether a class action lawsuit will be filed against Onglyza remains to be seen, but the potential is there. The manufacturers, Bristol-Myers Squibb (BMS) and AstraZeneca (AZ), are being sued over allegations that they failed to warn patients about heart failure, a serious complication associated with the drug.

AstraZeneca and BMS are facing more than a dozen lawsuits from people who have suffered serious heart complications after taking Onglyza. Some of these claims allege fraudulent marketing methods and other more mundane allegations, such as the manufacturer's failure to conduct sufficient pre-market clinical trials to demonstrate the drug's cardiovascular safety.

The FDA recommended that manufacturers conduct the appropriate safety studies before allowing a new drug on the market, but BMS and AZ ignored the advice. They sold Onglyza in 2009 without conducting any cardiovascular studies. Thousands of patients may have been exposed to heart failure.

The FDA also recommended that Onglyza carry a more specific warning about the increased risk of heart failure, but BMS and AZ ignored that advice.

Preparing for your Onglyza lawsuit

Whether you are a patient, family member, or healthcare provider, you may want to consider filing an Onglyza lawsuit. This medication is a popular type 2 diabetes medication, but has been associated with serious side effects. Some of these side effects include heart failure.

If you or a loved one has experienced heart failure while taking Onglyza, you may be eligible to file a lawsuit. Your attorney can help you determine if you have a valid claim. You may be able to receive compensation for medical costs, lost income, and pain and suffering.

Onglyza lawsuits allege that the drug was marketed without warnings about the risks of heart failure. It is estimated that there are hundreds of Type 2 diabetes patients who could file a lawsuit.

The FDA began an investigation into the safety of Onglyza after a study in the New England Journal of Medicine linked the drug to an increased risk of heart failure. It also cited an increased risk of pancreatitis and pancreatic cancer. The FDA recommended that the warning label be updated to include information about heart failure. However, the drug's manufacturer, Bristol-Myers Squibb (BMS), resisted the change.

Vues 191
😀 😁 😂 😄 😆 😉 😊 😋 😎 😍 😘 🙂 😐 😏 😣 😯 😪 😫 😌 😜 😒 😔 😖 😤 😭 😱 😳 😵 😠 🤔 🤐 😴 😔 🤑 🤗 👻 💩 🙈 🙉 🙊 💪 👈 👉 👆 👇 🖐 👌 👏 🙏 🤝 👂 👃 👀 👅 👄 💋 💘 💖 💗 💔 💤 💢
Vous aimerez aussi